Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00432-020-03448-8.pdf
Reference33 articles.
1. Affolter T, Llewellyn HP, Bartlett DW et al (2019) Inhibition of immune checkpoints PD-1, CTLA- 4, and IDO1 coordinately induces immune- mediated liver injury in mice. PLoS ONE 14:e0217276
2. Attia P, Phan GQ, Maker AV et al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T lymphocyte antigen-4. J Clin Oncol 23:6043–6053
3. Cheung V, Gupta T, Payne M et al (2019) Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Front Gastroenterol 10:364–371
4. Hellmann MD, Paz-Ares L, Caro RB et al (2019) Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381:2020–2031
5. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med 363:711–723
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Effectiveness of immunosuppressant use for the treatment of immune checkpoint inhibitor-induced liver injury: A systematic review and meta-analysis;Frontiers in Oncology;2023-03-24
2. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System;Clinical Therapeutics;2023-02
3. Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives;Frontiers in Pharmacology;2023-01-09
4. Analysis of Hepatic Adverse Event in Patients Treated with Immune Checkpoint Inhibitor;Journal of Korean Society of Health-System Pharmacists;2022-11-30
5. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis;Expert Opinion on Drug Safety;2022-10-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3